Assessment of tumor heterogeneity in treatment-naive adrenocortical cancer patients using super(18)F-FDG positron emission tomography

• Published in: Endocrine 2016-09, Vol.53 (3), p.791-800
• Main Authors: Werner, Rudolf A, Kroiss, Matthias, Nakajo, Masatoyo, Muegge, Dirk O, Hahner, Stefanie, Fassnacht, Martin, Schirbel, Andreas, Bluemel, Christina, Higuchi, Takahiro, Papp, Laszlo, Zsoter, Norbert, Buck, Andreas K, Bundschuh, Ralph A, Lapa, Constantin
• Format: Article
• Language: English
• ISSN: 1355-008X; 1559-0100
• DOI: 10.1007/s12020-016-0970-1

As an orphan malignancy, only limited treatment options are available in adrenocortical carcinoma (ACC). Non-invasive risk assessment has not been described but may be of value to stratify patients for treatment. We aimed to evaluate the potential value of intra-individual tumor heterogeneity as assessed by super(18)F-fluorodeoxyglucose ( super(18)F-FDG) positron emission tomography/computed tomography (PET/CT) for outcome prediction in treatment-naive ACC patients. Ten patients with primary diagnosis of ACC were included in this study. Prior to any treatment initiation, baseline super(18)F-FDG PET scans were performed. Tumor staging was performed using the European Network for the Study of Adrenal Tumors (ENS). Intratumoral heterogeneity of the primary tumor was assessed by manual segmentation using conventional PET parameters (standardized uptake values and tumor-to-liver ratios) and textural features. The impact of tumoral heterogeneity based on pre-therapeutic super(18)F-FDG PET to predict progression-free (PFS) and overall survival (OS) was evaluated by receiver operating characteristic analysis. On average, tumor recurrence or progression was detected after median of 561 days (range 71-1434 days) after the pre-therapeutic baseline PET scan. 50 % of the patients died of ACC within the follow-up period (mean 983 plus or minus 404 days). Pre-therapeutic tumor volume was associated with PFS (r = -0.67, p = 0.05) and Ki67 index with OS (r = -0.66, p = 0.04). ENS tumor stage was the only parameter to correlate with both PFS and OS (r = -0.82, p = 0.001, and r = -0.72, p = 0.01, respectively). In the subgroup of patients without distant metastases (ENS stages II and III), age and pre-therapeutic tumor volume correlated significantly with PFS (r = 0.96, p = 0.01 and r = -0.93, p = 0.02, respectively) and OS (r = 0.95, p = 0.02 and r = -0.90, p = 0.04, respectively). None of the investigated classic or textural PET parameters predicted PFS or OS. In this pilot study in treatment-naive ACC patients, conventional super(18)F-FDG PET-derived parameters and textural tumor heterogeneity features were not suitable to identify high-risk patients.